Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide.

Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “Whether customers are trying to develop a new drug or seeking to improve the release characteristics of an existing drug, our lyophilization and flash-release technology are there to help,” said Protheragen-ING’s Chief Scientist.

Over the past decade, the use of the freeze-drying process in pharmaceuticals, biopharmaceuticals and nanoderived therapeutics and their translation into commercially viable products has been proven to be highly effective in terms of maintaining the overall stability of pharmaceutical formulations. The major role of lyophilization technology here is to transform a drug into a solid powder or film form by freezing the drug solution and removing the water under a vacuum.

Meanwhile, the flash-release technology comes into play by empowering the drug to be released at a controlled rate over a given period. Oral fast-disintegrating dosage forms, also known as fast-melt, fast-disintegrating or fast-dissolving, are a relatively novel dosage technology that involves the rapid disintegration or dissolution of the dosage form, be it a tablet or a capsule, into a solution or suspension in the mouth without the need for water.

With the combination of these two methods, better efficacy and therapeutic results can be ultimately achieved. Overall, the freeze-dried rapid-release formulations by Protheragen-ING offer several benefits:

l They enhance the drug’s stability, prolong its shelf life, and boost its bioavailability.

l These formulations allow the medication to be absorbed into the body at a regulated release rate, leading to improved therapeutic outcomes.

l They make drug therapy more accessible for patients, thus increasing convenience and adherence to treatment plans.

A wide range of lyophilized flash-release formulation types can be developed by Protheragen-ING, which include: particles, nanoparticles, films, microspheres, and fiber bundles. Moreover, Protheragen-ING’s expert team can design and develop the most appropriate lyophilized flash release formulations based on client's needs and requirements.

A typical formulation development process would cover the following steps: initial consultation, formulation design, process optimization, analytical testing, scale-up and manufacturing.

About Protheragen-ING

With its cutting-edge equipment and experienced expert team, Protheragen-ING aims to provide precise analytical services for customers worldwide, guaranteeing accuracy and reliability. Currently, Protheragen-ING provides products and services like API products, pharmaceutical excipients, veterinary products, chemical products, intermediates, active pharmaceutical ingredients services, drug formulation development, drug delivery system development, anti-tumor API, hypoglycemic API, API for parkinson's disease, natural extract, chemical contract manufacturing, and drug analysis services.